Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases

(2015) Man Cai Wang et al.   MEDICINE

Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease

(2014) C. J. M. Williams et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab

(2014) Reuben Mari Valenzuela et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

(2014) Séverine Vermeire et al.   LANCET

Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials

(2013) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease

(2013) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Central nervous system lymphoma associated with natalizumab

(2013) Angelika Na et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ulcerative colitis

(2013) A. C. Ford et al.   BMJ-British Medical Journal

Natalizumab-associated complication? First case of peripheral T cell lymphoma

(2012) Jeffrey Schowinsky et al.   ACTA NEUROPATHOLOGICA

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

(2012) Paul J Rutgeerts et al.   GUT

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

(2011) Khurram J Khan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study

(2011) Asit Parikh et al.   INFLAMMATORY BOWEL DISEASES

Primary central nervous system lymphoma in a patient treated with Natalizumab

(2010) Remy Phan-Ba et al.   ANNALS OF NEUROLOGY

Diagnosis of melanoma under concomitant natalizumab therapy

(2010) Bettina M Prinz Vavricka et al.   Multiple Sclerosis Journal

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

(2009) J.F. Rahier et al.   Journal of Crohns & Colitis

Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin

(2008) Brian G. Feagan et al.   Clinical Gastroenterology and Hepatology